Dr. Andreas Rummel is Senior Group Leader at the Institut für Toxikologie (https://www.mhh.de/institute-zentren-forschungseinrichtungen/institut-fuer-toxikologie/arbeitsgruppen/ag-rummel) at the Medizinische Hochschule Hannover (MHH), Hannover, Germany. Dr Rummel obtained his PhD in biochemistry with the thesis entitled Characterization of the Cell Binding Domain of Clostridial Neurotoxins. In 2003, he joined the Institut für Toxikologie at MHH as a postdoctoral fellow, and in 2004, he joined toxogen GmbH (www.toxogen.de), a small enterprise developing clostridial neurotoxins as therapeutics and diagnostic tools.
Dr. Rummel has contributed significantly to advance knowledge on structure-activity relationship of botulinum neurotoxins (BoNTs) as well as their detection, illustrated by >50 original peer-reviewed publications and 13 review articles/book chapters. He is editor of the Botulinum Neurotoxins book series. His recognition is well documented by >3800 citations. He is member of the editorial board of Toxins (ISSN 2072-6651) since 01/2016 and has also served as ad hoc reviewer for numerous journals, including Nature, PLoS One, and FEBS. In addition, Dr. Rummel is sole or co-inventor of 8 patent applications of which 4 patent families were granted worldwide. In 2006 he received the start-up award Hochschul-Impuls.
Dr. Rummel served as Scientific Sub-Committee Co-Chair of the TOXINS 2015 conference and Scientific Sub-Committee Chair of the TOXINS 2017 conference. He has been elected as At-large Director of the International Neurotoxin Association (INA) from 2015-2019 and is currently elected Secretary of INA. He is also member of the International Scientific Programme Committee for the European Workshops on Bacterial Protein Toxins (ETOX).
Dr. Rummel’s ORCHID page can be found here: https://orcid.org/0000-0002-0645-1641.